panitumumab

S&P Equity Research analyst Frank DiLorenzo noted that the response rate for panitumumab arm was 8% versus a response rate of 10.8% for Erbitux, a cancer drug marketed by ImClone Systems and Bristol-Myers Squibb.

Amgen's Cancer Drug May Take Share From Erbitux 2006

"Clinical data suggests that panitumumab is as effective as Erbitux, but its milder safety profile and more convenient dosing could make it a preferred choice among oncologists," noted Anderson.

Bristol-Myers Squibb Shares Look Expensive 2006

The U.S. Food and Drug Administration granted priority review status to Amgen's colon cancer drug, panitumumab, the company announced after Monday's closing bell.

Eye On Stocks For Tuesday, June 13Eye On Stocks For Tuesday, June 13, 2006 2006

Amgen said this morning Phase III trial data showed that panitumumab "significantly improved" survival rates in colon cancer patients who previously failed chemotherapy.

Amgen's Cancer Drug May Take Share From Erbitux 2006

Sales of Erbitux, a cancer drug licensed from ImClone Systems, could rise as it is expanded into other indications, but growth could be held in check by Amgen's panitumumab.

Bristol-Myers Squibb Shares Look Expensive 2006

"The delay of PACCE data for panitumumab until late 2006 removes the only major near-term pipeline catalyst for Amgen," the firm noted.

Drug Approvals, Earnings Energize Drug Stocks 2006

The pending merger will allow Amgen to reap all the profits from promising cancer-drug panitumumab, currently in late-stage trials.

Biotech Stocks Show Some Muscle 2006

"We are not convinced the FDA will grant priority review due the lack of an unmet medical need in refractory mCRC with the availability of Erbitux and the seemingly comparable efficacy of panitumumab," wrote analyst David Molowa.

Eye On Stocks For Tuesday, June 13Eye On Stocks For Tuesday, June 13, 2006 2006

"At this point, we expect Erbitux to maintain its share in combination with chemo to treat colorectal cancer and think panitumumab could take some share in the monotherapy area only."

Amgen's Cancer Drug May Take Share From Erbitux 2006

Typically, patients who fail 5-FU, oxaliplatin, irinotecan, and bevacizumab-containing therapies, and who have wild-type KRAS status receive EGFR monoclonal antibody therapy with either cetuximab or panitumumab.

BioSpace.com Featured News and Stories 2010